Academic Bibliography

Mark

The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer

Eric Van Cutsem, Robert J Mayer, Stéphanie Laurent (UGent) , Robert Winkler, Cristina Grávalos, Manuel Benavides, Federico Longo-Munoz, Fabienne Portales, Fortunato Ciardiello, Salvatore Siena, et al.

(2018) EUROPEAN JOURNAL OF CANCER. 90. p.63-72

Mark

Radiotherapy access in Belgium : how far are we from evidence-based utilisation?

Yolande Lievens (UGent) , H De Schutter, K Stellamans, M Rosskamp and L Van Eycken

(2017) EUROPEAN JOURNAL OF CANCER. 84. p.102-113

Mark

Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma

Birgit Geoerger, Christophe Bergeron, Lia Gore, Leonard Sender, Ira J Dunkel, Cynthia Herzog, Lieve Brochez (UGent) , Ofelia Cruz, Karsten Nysom, Elmer Berghorn, et al.

(2017) EUROPEAN JOURNAL OF CANCER. 86. p.358-363

Mark

The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy

Lieve Brochez (UGent) , INES CHEVOLET (UGent) and Vibeke Kruse (UGent)

(2017) EUROPEAN JOURNAL OF CANCER. 76. p.167-182

Mark

Menopausal hormone therapy and cancer risk : an overestimated risk?

Johanna Simin, Rulla Tamimi, Jesper Lagergren, Hans-Olov Adami and Nele Brusselaers (UGent)

(2017) EUROPEAN JOURNAL OF CANCER. 84. p.60-68

Mark

journalArticle
A1
open access

Cost-effectiveness analysis in melanoma detection: a transition model applied to dermoscopy

Isabelle Tromme, Catherine Legrand, Brecht Devleesschauwer (UGent) , Ulrike Leiter, Stefan Suciu, Alexander Eggermont, Laurine Sacré, Jean-François Baurain, Luc Thomas, Philippe Beutels, et al.

(2016) EUROPEAN JOURNAL OF CANCER. 67. p.38-45

Mark

Melanoma burden by melanoma stage : assessment through a disease transition model

Isabelle Tromme, Catherine Legrand, Brecht Devleesschauwer (UGent) , Ulrike Leiter, Stefan Suciu, Alexander Eggermont, Julie Francart, Frédéric Calay, Juanita A Haagsma, Jean-François Baurain, et al.

(2016) EUROPEAN JOURNAL OF CANCER. 53. p.33-41

Mark

Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a 'chemosensitive' relapse: a single-arm phase II study (EORTC-08061)

Fatma Abdelraouf, Egbert Smit, Baktiar Hasan, Jessica Menis, Sanjay Popat, Jan Van Meerbeeck (UGent) , Veerle Surmont (UGent) , Paul Baas and Mary O'Brien

(2016) EUROPEAN JOURNAL OF CANCER. 54. p.35-39

Mark

Risk stratification in febrile neutropenic episodes in adolescent/young adult patients with cancer

Robert S Phillips, Kaljit Bhuller, Lillian Sung, Roland A Ammann, Wim JE Tissing, Thomas Lehrnbecher, Lesley A Stewart, on behalf of the PCNICC Collaboration, Tieneke Bauters (UGent) and Genevieve Laureys (UGent)

(2016) EUROPEAN JOURNAL OF CANCER. 64. p.101-106

Mark

Responding to the cancer crisis: expanding global access to radiotherapy: a Lancet Oncology Commission

R Atun, D Jaffray, M Barton, M Baumann, B Vikram, F Bray, T Hanna, F Knaul, Yolande Lievens (UGent) , B O'Sullivan, et al.

(2015) EUROPEAN JOURNAL OF CANCER. 51(suppl. 3). p.S707-S708

Academic Bibliography

The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer

Radiotherapy access in Belgium : how far are we from evidence-based utilisation?

Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma

The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy

Menopausal hormone therapy and cancer risk : an overestimated risk?

Cost-effectiveness analysis in melanoma detection: a transition model applied to dermoscopy

Melanoma burden by melanoma stage : assessment through a disease transition model

Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a 'chemosensitive' relapse: a single-arm phase II study (EORTC-08061)

Risk stratification in febrile neutropenic episodes in adolescent/young adult patients with cancer

Responding to the cancer crisis: expanding global access to radiotherapy: a Lancet Oncology Commission

Contents

Support

Contact